NCT05880043View on ClinicalTrials.gov

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid TumorsRelapsed/Refractory Non-Hodgkin LymphomaRelapsed/Refractory Multiple Myeloma
Interventions
DRUG

GIC-102

GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle

DRUG

GIC-102

GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle

Trial Locations (4)

Unknown

RECRUITING

Korea University Anam Hospital, Seoul

RECRUITING

Seoul Asan Medical center, Seoul

NOT_YET_RECRUITING

Seoul Asan Medical center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

GI Cell, Inc.

INDUSTRY